# Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

> **NCT06409702** · PHASE4 · RECRUITING · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 59 (estimated)

## Conditions studied

- Newly Diagnosed
- High Risk
- MRD
- Multiple Myeloma

## Interventions

- **DRUG:** Carfilzomib
- **DRUG:** Daratumumab
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone
- **DRUG:** VRD for first-cycle induction therapy

## Key facts

- **NCT ID:** NCT06409702
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-12
- **Primary completion:** 2027-11-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 59 (ESTIMATED)
- **Last updated:** 2025-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06409702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06409702, "Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06409702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*